Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse; Umar Farooq; Roni Shouval; Anusha Vallurupalli; Amy Moskop; Caron A. Jacobson; Frederick Locke; John H. Baird; Paolo Strati; Dilan A. Patel; Saurabh Dahiya; Michael T. Hemmer; Brad Du; Clare Spooner; Jenny J. Kim; Debbie L. Mirjah; Zhen-Huan Hu; Marcelo C. Pasquini; Yi Lin

doi:10.1182/blood-2024-207976

Background: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are known safety concerns following chimeric antigen receptor (CAR) T-cell therapy. Axi-cel, a CAR T-cell therapy approved in the US for adults with R/R LBCL after ≥ 1 line of prior therapy (2L+), has been administered in the outpatient setting, where a common cause for post-infusion hospital admissions were CAR T-cell-related toxicities (Furqan et al., 2024). Due to reimbursement policies in the US, patients at higher risk for safety events requiring inpatient care within 3 days of infusion may not be ideal candidates for outpatient care. We sought to identify what pre-infusion characteristics may put patients more at risk for developing early CRS and ICANS after axi-cel. Methods: Patients receiving axi-cel for R/R LBCL 2L+ between 01/2021−10/2023 registered in the Center for International Blood and Marrow Transplant Research (CIBMTR) observational database were potentially eligible for analysis. Patients with prior non-transplant cellular therapy or missing data for analysis were excluded. Primary endpoints were onset of early CRS and early ICANS, defined as an any grade event within 3 calendar days of axi-cel infusion (date of infusion is defined as Day 0 and onset of CRS/ICANS before the end of Day 3 is an early event). Early Grade ≥ 2 and early Grade ≥ 3 CRS and ICANS (onset of CRS/ICANS before the end of Day 3 and maximum Grade ≥ 2 and ≥ 3 per ASTCT Criteria) were also evaluated. Patient demographics, ECOG PS, comorbidities, disease characteristics at diagnosis and prior to infusion, line of therapy (LoT), lab assessments prior to infusion, and infusion-related attributes were evaluated by univariate screening and multivariable regression for development of early CRS or early ICANS. Results: A total of888 patients from 105 centers were included in the analysis. Median age was 63 years (45% ≥ 65 years) and 66% were male. At LBCL diagnosis, 22% of patients had a histological transformation. Prior to infusion, 5% of patients had ECOG PS ≥ 2 and 70% had at least 1 clinically significant comorbidity. Half (50%) of patients received axi-cel with 1 prior LoT (2L) and 10% of patients underwent a prior autologous hematopoietic cell transplant. Median time from leukapheresis to infusion was 30 days (interquartile range [IQR] 27−34). Bridging therapy of any type was administered in 59%, and systemic bridging therapy in 48%, of patients and 14% of patients were intended to be treated in the outpatient setting. Thirty percent of patients had chemo-sensitive disease prior to infusion. Median follow-up post-infusion was 12.3 months (range 3−38). Median time to onset of CRS was 4 days (IQR 2−6) and 84% of patients experienced CRS at any time. Early any grade (Grade ≥ 3) CRS was observed in 47% (3%) of patients. In the multivariate analysis of early any grade CRS, only prior LoT (≥ 2 vs 1) was associated with lower risk (OR 0.71; 95% CI 0.55−0.94), but this association was not seen in the analyses of early Grade ≥ 2 nor early Grade ≥ 3 CRS. Notably, 47% and 52% of patients with ≥ 2 vs 1 prior LoT, respectively, only experienced early Grade 1 CRS (defined as fever only). In the analysis of early Grade ≥ 3 CRS, only ECOG PS 0−1 was associated with lower risk vs patients with ECOG PS ≥ 2 (OR 0.17; 95% CI 0.06−0.48). Median time to onset of ICANS was 7 days (IQR 5−9) and 47% of patients experienced ICANS at any time. Early any grade (Grade ≥ 3) ICANS occurred in 9% (5%) of patients. After multivariate adjustment, age < 65 vs ≥ 65 (OR 0.38 [95% CI 0.23−0.62]) and 1 vs ≥ 2 prior LoT (OR 0.58 [95% CI 0.36−0.95]) were associated with lower risk of early any grade ICANS. Age < 65 vs ≥ 65 was also associated with lower risk of early Grade ≥ 3 ICANS (OR 0.31 [95% CI 0.15−0.61]), as was ECOG PS 0−1 vs ECOG PS ≥ 2 (OR 0.30 [95% CI 0.11−0.83]). Comorbidities were evaluated and no significant associations with early CRS nor early ICANS were found. Conclusions: This analysis of readily available clinical variables in a real-world contemporary cohort of patients treated with axi-cel demonstrates that younger patients and patients with better ECOG PS have lower risk of early CRS and early ICANS. Axi-cel in 2L setting, vs 3L+, is associated with lower risk of early any grade ICANS and comparable early Grade ≥ 2 CRS, but a higher risk of early fever. These results further enable a more informed decision of patient selection for physicians, which is critical for the success of outpatient administration. Strouse:Seagen: Research Funding; Bristol Meyer Squibb: Research Funding; Janssen: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Poseida: Research Funding. Farooq:Regeneron: Research Funding; Caribou, MorphoSys: Consultancy; Caribou, Gilead/Kite: Honoraria. Jacobson:Instil Bio: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Miltenyi: Consultancy; MorphoSys: Consultancy; Synthekine: Consultancy; Pfizer: Research Funding; Novartis: Consultancy; Ipsen: Consultancy; ImmPACT Bio: Consultancy; Daiichi Sankyo: Consultancy; Caribou Biosciences: Consultancy; Bristol Myers Squibb/Celgene: Consultancy; Abintus Bio: Consultancy; ADC Therapeutics: Consultancy; AbbVie: Consultancy. Locke:Imedex: Honoraria; Cowen: Consultancy; Clinical Care Options Oncology: Honoraria; Society for Immunotherapy of Cancer: Honoraria; Moffitt Cancer Center: Patents & Royalties; Communications CARE Education: Honoraria; Allogene: Other: Institutional, Research Funding; 2SeventyBio: Other: Institutional, Research Funding; Gerson Lehrman Group (GLG): Consultancy; Pfizer: Consultancy; Umoja: Consultancy; Aptitude Health: Honoraria; BioPharma Communications CARE Education: Honoraria; A2: Consultancy; CERo Therapeutics: Research Funding; Janssen: Consultancy; EcoR1: Consultancy; American Society of Hematology: Honoraria, Other: travel, accomodation, expenses; Kite, a Gilead Company: Consultancy, Other: institutional, travel, accomodation, expenses, Research Funding; Caribou: Consultancy; Calibr: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Bluebird Bio: Consultancy; Amgen: Consultancy; Allogene: Consultancy, Research Funding; Iovance: Consultancy; Legend Biotech: Consultancy; Novartis: Consultancy, Research Funding; Sana: Consultancy; National Cancer Institute: Other: Institutional, Research Funding; Leukemia and Lymphoma Society Scholar in Clinical Research: Other: Institutional, Research Funding. Baird:Curio Sciences: Honoraria; Genentech: Research Funding; Regeneron: Research Funding; Janssen: Research Funding; Kite, a Gilead company: Research Funding, Speakers Bureau. Strati:ALX Oncology: Research Funding; Roche-Genentech: Consultancy; Hutchison MediPharma: Consultancy; Ipsen: Consultancy; Kite, a Gilead company: Consultancy, Research Funding; Sobi ADC Therapeutics: Consultancy, Other: Travel, accommodations, expenses, Research Funding; TG Therapeutics: Consultancy; Acerta-Astrazeneca: Consultancy, Research Funding; Abbvie-Genmab: Consultancy. Dahiya:Kite, a Gilead Company: Consultancy, Research Funding. Hemmer:Kite, a Gilead company: Current Employment; Gilead Sciences: Current equity holder in publicly-traded company. Du:Kite, a Gilead company: Current Employment; Gilead Sciences: Current equity holder in publicly-traded company. Spooner:Kite, a Gilead Company: Current Employment; Gilead Sciences: Current equity holder in publicly-traded company. Kim:Kite Pharma: Current Employment; Gilead Sciences: Current equity holder in publicly-traded company. Mirjah:Kite, a Gilead company: Current Employment; Gilead Sciences: Current equity holder in publicly-traded company. Hu:Gilead Sciences: Current equity holder in publicly-traded company; Kite, a Gilead Company: Current Employment. Pasquini:Janssen: Research Funding; Novartis: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Kite, a Gilead Company: Honoraria, Research Funding. Lin:Regeneron: Consultancy; Celgene: Consultancy, Research Funding; NexImmune: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Legend: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Sanofi: Consultancy; Genentech: Consultancy; Janssen: Consultancy, Research Funding; Caribou: Membership on an entity's Board of Directors or advisory committees.

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

View Online

Abstract

Details

Metrics